Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Cost-Effectiveness Analysis of Empagliflozin In The Treatment Of T2d With Previous Cardiovascular Disease In Italy — Sergio Iannazzo (2017) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Cost-Effectiveness Analysis of Empagliflozin In The Treatment Of T2d With Previous Cardiovascular Disease In Italy
Shared by
Aldo Maggioni
Cost-Effectiveness Analysis of Empagliflozin In The Treatment Of T2d With Previous Cardiovascular Disease In Italy
Article
2017
en
Authors
+1 more
SI
Sergio Iannazzo
EM
Edoardo Mannucci
OR
Odette S. Reifsnider
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2019
Budget impact analysis of empagliflozin in T2D patients with a previous cardiovascular disease
Sergio Iannazzo
,
Aldo Maggioni
,
Edoardo Mannucci
Article
2017
Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study
Sergio Iannazzo
,
Edoardo Mannucci
,
Odette S. Reifsnider
,
Aldo Maggioni
Article
1993
Cost-Effectiveness of Antihypertensive Treatment
Magnus Johannesson
,
John Wikstrand
,
Bengt Jønsson
,
G. Berglund
,
Jaakko Tuomilehto
PharmacoEconomics
Article
2021
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
Pietro Ferrara
,
Paolo Angelo Cortesi
,
Danilo Di Laura
,
Aldo Maggioni
,
LG Mantovani
Article
2019
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Masahiro Kobayashi
,
Masatoshi Kudo
,
Namiki Izumi
,
Shuichi Kaneko
,
Mie Azuma
,
Ronda Copher
,
Genevieve Meier
,
Janice Pan
,
Mika Ishii
,
Shunya Ikeda
Discussion(0)
No comments yet. Be the first to comment.